Page 1

IN bio IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update November 10 , 2021 • Closed initial public offering raising net proceeds after expenses of $ 32.3 million . • Added two new independent Directors and increased diversity across our Board of Directors . • Completed patient dosing of the first cohort of a Phase 1 clinical trial of INB - 100 in leukemia patients undergoing hemopoietic stem cell transplant . • Announced peer - reviewed publication of preclinical data for INB - 200 in Scientific Reports , a Nature Portfolio journal . NEW YORK , Nov. 10 , 2021 ( GLOBE NEWSWIRE ) -- IN8bio , Inc. ( Nasdaq : INAB ) , a clinical - stage biopharmaceutical company focused on the discovery and development of innovative gamma - delta T cell therapies utilizing its DeltEx platform , today announced financial results and operational highlights for the third quarter ended September 30 , 2021. In addition , the Company provided an overview of recent corporate developments . " Our IPO has provided the capital to enable us to advance our clinical programs for INB - 100 in leukemia and INB - 200 in newly diagnosed glioblastoma ( GBM ) and other solid tumors as well as progress our preclinical - stage assets , " said William Ho , Chief Executive Officer and co - founder of IN8bio . " Both of our clinical programs continue to progress and we took the opportunity during the required safety observation period for the allogeneic INB - 100 trial to improve our manufacturing processes and overall gamma - delta T cell yield . We look forward to the continued advancement of our clinical and preclinical programs and to providing updates on them in the future . " Third Quarter Business Highlights & Corporate Updates • In July 2021 , IN8bio appointed Emily Fairbairn and Luba Greenwood as two independent members of the Company's Board of Directors . Ms. Fairbairn is currently a principal of Transcend Partners and was co - founder and CEO of Ascend Capital . Ms. Greenwood serves as Managing Partner of Binney Street Capital LLC , a venture capital fund established by the Dana Farber Cancer Institute , and as CEO of LUCA Biologics . • In August 2021 , IN8bio closed its initial public offering , in which it issued and sold 4,000,000 shares of common stock at a public offering price of $ 10.00 per share . The net proceeds to the Company were approximately $ 32.3 million , after deducting underwriting discounts , commissions and offering expenses . • In August 2021 , IN8bio completed dosing of the first cohort of INB - 100 , a Phase 1 clinical trial of donor - derived allogeneic gamma - delta T cells in leukemia patients undergoing haploidentical hematopoietic stem cell transplant ( HSCT ) . No severe adverse infusion reactions , cytokine release syndrome , neurotoxicity ( or ICANS ) or dose - limiting toxicities were observed . Episodes of mild - to - moderate acute skin graft - versus - host - disease ( GVHD ) responsive to standard therapy have been observed . Additional patients will be enrolled at the first dose - level to further assess these events and any potential relationship to the ongoing positive clinical responses observed in the INB - 100 treated patients . Skin biopsies were consistent with the expected pathology in post - HSCT GvHD and the vast majority of immune cell infiltration were alpha - beta T cells . All three patients treated with INB - 100 continue in remission with the first two patients beyond 18- and 16 - months post - transplant , respectively . The Company continues to expect to report initial results from the first cohort in this Phase 1 trial in 2022 , with topline results for all cohorts in 2023 . • In September 2021 , IN8bio announced the peer - reviewed publication of preclinical results that it believes provides foundational support for the use of its DeltEx Drug Resistant Immunotherapy ( DRI ) in newly diagnosed GBM . This work , published in Scientific Reports , a Nature Portfolio journal , focused on the use of gamma - delta T cells genetically engineered to be chemotherapy resistant through the addition of an 06 - Methylguanine - DNA Methyltransferase ( MGMT ) . Concurrent dosing of DRI cells with temozolomide ( TMZ ) resulted in a significant improvement in survival outcomes in mice over either monotherapy alone in both classical and mesenchymal primary high - grade gliomas . • In October and November 2021 , the Company presented updates on its programs at the 2021 Advanced Therapies Congress and at the 13th Annual Protein and Antibody Engineering Summit ( PEGS ) Europe . Upcoming Scientific Presentations • 36th Annual Meeting of the Society for Immunotherapy of Cancer ( SITC ) , November 10 - 14 , 2021 . • 26th Annual Meeting of the Society of Neuro - Oncology ( SNO ) , November 18 - 21 , 2021 .